【摘要】 <正> 早在1935年就已发现成人的精液和前列腺组织中含有高活力的酸性磷酸酶,而在睾丸、精囊腺以及副睾等组织中无此现象。藉比色法测定的血清前列腺酸性磷酸酶(PACP),因缺乏特异性,仅用于前列腺癌复发的监测,无诊断价值。近年来,发现了一些前列腺肿瘤标记物,如γ精原蛋白(γ-sm),前列腺抗原(PA)以及藉放射免疫法测定的前列腺酸性磷酸酶(PAP)等,在前列腺更多还原

【Abstract】 By means of colorimetric assay, total serum acid phosphatase activity and prostatio acid phosphatase ratio(PACP/ACP) was studied in 12 patients with untreated prostatic cancer and 32 with benign prostatic diseases including 30 prostatic hypertrophy; 1 prostatic stone and 1 prostatitis. When 0.4 was applied as a cut off level, elevated PACP/ACP ratio was found in 8 of the 12 cancer patients, and 2 of the 32 benign patients. There was significant difference between the two groups by chi square (X~2=25.68, P<0.01). The diagnostic efficiency of PACP/ACP was 62.6%, which was higher than that of γ-seminoprotein (γ-sin) or prostatic acid phosphatase (PAP) measured by radioimmunoassay in this series. It was only in the cancer group that there was a significant correlation between ACP and PACP (r=0.9922, P<0.01). However, neither in the benign control group in which PACP was elevated (>0.8KA), nor in the control group in which PACP was normal (<0.8KA), no correlation between ACP and PACP was found (r=-0.0242, 0.3985, P>0.05). Therefore, it was suggested that PACP/ACP ratio was a new valuable tumor marker. When PACP/ACP was ligher than 0.4, prostatic cancer should be strongly suspected. The combination of PACP/ACP, γ-sin and PAP increased the diagnostic accuracy of the cancer.更多还原